Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting

An announcement from Amylyx Pharmaceuticals Inc ( (AMLX) ) is now available.

On June 5, 2025, Amylyx Pharmaceuticals Inc. held its Annual Meeting of Stockholders where three key proposals were voted on. The stockholders elected Karen Firestone, Justin Klee, and Bernhardt Zeiher, M.D. as Class I directors for a three-year term. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on an advisory basis, the compensation of the Company’s named executive officers.

The most recent analyst rating on (AMLX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.

Spark’s Take on AMLX Stock

According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.

The overall stock score of 58.7 reflects significant financial challenges, despite positive technical indicators and clinical advancements. The company’s financial instability and cash flow issues are the most significant risks, although ongoing trials and a strengthened cash position offer potential long-term growth opportunities.

To see Spark’s full report on AMLX stock, click here.

More about Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for neurodegenerative diseases.

Average Trading Volume: 912,116

Technical Sentiment Signal: Buy

Current Market Cap: $456.4M

For an in-depth examination of AMLX stock, go to TipRanks’ Stock Analysis page.